WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

24.04.2017: Ad-hoc release: WILEX AG plans rights issue using authorised capital....More

More information on the capital increase can be found here.

 

 

 

Seite gelesen: 304 | Heute: 2